Sabra Health Care price target raised to $18 from $16 at Truist

Truist raised the firm’s price target on Sabra Health Care (SBRA) to $18 from $16 and keeps a Buy rating on the shares. The firm cites the company’s Q2 FFO beat while also noting that it is assuming its managed portfolio occupancy gradually improves over the next several quarters and eventually stabilizes at 87.5% at the end of 2025, the analyst tells investors in a research note. It is also “reasonable to assume” that Sabra’s relative discount vs. Omega (OHI) can narrow a bit, particularly if its near-term growth is as competitive as projected, Truist added.